PLC Systems Demonstrating RenalGuard(R) at EuroPCR 2013
Investigator Presenting RenalGuard Data During "Interventions for Heart Disease" Session
MILFORD, MA -- (Marketwired) -- 05/16/13 -- PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies, today announced it will demonstrate its product, RenalGuard®, at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EuroPCR attracts more than 11,000 clinicians and medical professionals from around the world. The meeting will take place in Paris, France from May 21-24, 2013.
In addition, RenalGuard Therapy® has been selected to be presented as part of EuroPCR's Interventions for Structure Heart Disease session.
Presentation Title: Minimizing Acute Kidney Injury During TAVI Procedures
Presenter: Dr. Vaikom Mahadevan, Manchester Royal Infirmary
Date / Time: Thursday, May 23, 2013 at 15:40
Location: Room 341
More information about Dr. Mahadevan's presentation can be found on the EuroPCR's website at http://www.europcr.com/page/europcr-2013-programme/456-new-interactive-programme.html.
About PLC Systems Inc.
PLC Systems Inc., headquartered in Milford, Mass., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard, has been developed to rapidly remove contrast dyes that are potentially toxic to patients undergoing certain cardiac and vascular imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard's effectiveness at preventing Contrast-Induced Nephropathy (CIN). RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by FDA.
This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if this clinical trial is completed, it may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, the need for additional financing, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2012, a copy of which is on file with the SEC.
PLC Systems, PLC Medical Systems, PLC, RenalGuard and RenalGuard Therapy are trademarks of PLC Systems Inc.
Source: PLC Systems, Inc.
Released May 16, 2013